Cart

YOUR CART IS EMPTY

Add research compounds to begin your order.

Peer-reviewed human trials and related publicationsSee approved evidence mapCompleted

Lancet

RET-STUDY-P003

Urva S, et al. Retatrutide multiple-ascending-dose Phase 1b study in type 2 diabetes. Lancet. 2022. DOI: 10.1016/S0140-6736(22)02033-5. PMID: 36354040. NCT04143802. https://pubmed.ncbi.nlm.nih.gov/36354040/

Study design

Record details

Design: Peer-reviewed human trials and related publications

Evidence record

Endpoints, findings, and limitations

Limitations

This study record is an evidence-index entry. Interpret the design, material, population or model, endpoints, findings, and limitations only within the linked approved source and compound evidence map; do not transfer outcomes across compounds, materials, cohorts, or models.

Reports and sources

Reference ledger

P003Peer-reviewed human trials and related publications

Lancet

Urva S, et al. Retatrutide multiple-ascending-dose Phase 1b study in type 2 diabetes. Urva S, et al. Retatrutide multiple-ascending-dose Phase 1b study in type 2 diabetes. Lancet. 2022. DOI: 10.1016/S0140-6736(22)02033-5. PMID: 36354040. NCT04143802. https://pubmed.ncbi.nlm.nih.gov/36354040/(2022). DOI: 10.1016/S0140-6736(22